Ueda, Tatsuki
Shiina, Sara
Iriguchi, Shoichi
Terakura, Seitaro http://orcid.org/0000-0002-1194-8046
Kawai, Yohei
Kabai, Ryotaro
Sakamoto, Satoko
Watanabe, Akira
Ohara, Kohei
Wang, Bo
Xu, Huaigeng
Minagawa, Atsutaka
Hotta, Akitsu http://orcid.org/0000-0002-2619-7441
Woltjen, Knut http://orcid.org/0000-0003-2293-1183
Uemura, Yasushi
Kodama, Yuzo
Seno, Hiroshi
Nakatsura, Tetsuya
Tamada, Koji
Kaneko, Shin http://orcid.org/0000-0003-2291-4586
Funding for this research was provided by:
Japan Agency for Medical Research and Development (Development of Innovative 679 Research on Cancer Therapeutics, Practical Research for Innovative Cancer Control, Core Center for iPS Cell Research)
National Cancer Center Research Fund
Article History
Received: 21 December 2021
Accepted: 21 October 2022
First Online: 12 December 2022
Competing interests
: S.K. is a founder, shareholder and director of Thyas Co., Ltd., and received research funding from Takeda Pharmaceutical Co., Ltd., Kirin Co., Ltd., Astellas Co., Ltd., Terumo Co., Ltd., Mitsui-soko Co., Ltd., KOTAI Biotechnologies, and Thyas Co., Ltd. K.T. is chief executive officer of Noile-Immune Biotech Inc. and receives research funding from it. The remaining authors declare no competing financial interests.